Itonic Holdings Ltd. (NASDAQ:ITOC) Sees Significant Drop in Short Interest

Itonic Holdings Ltd. (NASDAQ:ITOC) was the recipient of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totaling 10,047 shares, a decrease of 95.1% from the September 30th total of 206,400 shares. Based on an average trading volume of 26,939 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Itonic Stock Up 14.1%

Shares of ITOC stock traded up $0.37 during trading hours on Wednesday, reaching $3.02. 16,044 shares of the company traded hands, compared to its average volume of 118,562. The firm has a 50-day moving average price of $4.37 and a 200 day moving average price of $4.94. Itonic has a 12-month low of $2.33 and a 12-month high of $18.40.

Itonic (NASDAQ:ITOC) last released its earnings results on Wednesday, September 30th. The company reported ($0.75) EPS for the quarter. The business had revenue of $0.05 million for the quarter.

Itonic Company Profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.